Comparación de las manifestaciones oculares durante el contagio por COVID-19 y después de la vacunación

Vista sencilla de ítem
dc.contributor.advisorRey, Diana Valeria
dc.contributor.authorHernández Pacheco, Nicolle Daniela
dc.contributor.authorAguilar Serrano, Luisa Fernanda
dc.contributor.orcidHernández Pacheco, Nicolle Daniela [0000-0001-6865-5060]
dc.contributor.orcidAguilar Serrano, Luisa Fernanda [0000-0002-1550-977X]
dc.date.accessioned2024-06-04T22:04:23Z
dc.date.available2024-06-04T22:04:23Z
dc.date.issued2023-04
dc.description.abstractObjetivo: Identificar la frecuencia de manifestaciones generales y oculares en pacientes diagnosticados con COVID-19 y analizar los síntomas asociados a la vacunación. Metodología: Se diseñó un cuestionario de 15 preguntas sobre manifestaciones oculares asociadas a la COVID-19 y síntomas tras la vacunación. Se realizó un análisis descriptivo, incluyendo el uso de porcentajes y frecuencias para variables cualitativas. Se realizaron análisis bivariados según la relación entre las variables de interés. Resultados: Participaron en el estudio 270 personas cuyas edades fueron: menores de 18 años 10,7% (29), de 18 a 30 años 85,6% (231), de 31 a 40 años 3,3% (9) y mayores de 41 años 0,4% (1). De los cuales el 29,3% (79) fueron diagnosticados con COVID-19. Las manifestaciones generales y oculares se evaluaron en una escala de 0 a 4, en la que 1 correspondía a síntomas leves y 4 a síntomas incapacitantes. La pérdida del olfato y del gusto fue relatada como incapacitante en 7,03% (19), seguida de cefalea en 5,18% (14). En cuanto a las manifestaciones oculares, el dolor ocular obtuvo un porcentaje de 4,44% (12) en la escala 3, seguido de la sensibilidad a la luz en un 6,29% (17) en la escala 2. Los síntomas oculares reportados se presentaron principalmente entre 1 a 3 días en un 12,6% (34). El 95,6% (258) de los encuestados estaban vacunados contra el COVID-19. Los siguientes fueron los síntomas sistémicos más frecuentemente reportados como incapacitantes después de la vacunación: dolor de cabeza en 8,5% (23), seguido de dolor muscular en 8,1% (22). Dentro de las manifestaciones oculares predominó el prurito en un 1,4% (4), seguido de la sequedad ocular en un 1,1% (3). Estas manifestaciones se presentaron principalmente entre 1 a 3 días después de la vacunación en el 40% (108) de los participantes. Conclusiones: Si bien la vacunación contra el COVID-19 ha sido efectiva, persisten casos positivos en los que los síntomas reportados con mayor frecuencia han sido pérdida del olfato y del gusto, dolor de cabeza y secreción nasal; además, se ha informado dolor ocular incapacitante. En cuanto a los síntomas presentados después de la vacunación; destacan el dolor muscular, el dolor de cabeza y el picor de ojos.
dc.description.abstractenglishObjective: To identify the frequency of general and ocular manifestations in patients diagnosed with COVID-19 and to analyze the symptoms associated with vaccination. Methodology: A questionnaire with 15 questions on ocular manifestations associated with COVID-19 and symptoms after vaccination was designed. A descriptive analysis was carried out, including the use of percentages and frequencies for qualitative variables. Bivariate analyzes were performed according to the relationship between the variables of interest. Results: 270 people participated in the study whose ages were: under 18 years old 10,7% (29), from 18 to 30 years old, 85,6% (231), 31 to 40 years old, 3,3% (9), and older than 41 years 0,4% (1). Of which 29,3% (79) were diagnosed with COVID-19. General and ocular manifestations were evaluated on a scale from 0 to 4, in which 1 corresponded to mild symptoms and 4 to disabling symptoms. The loss of smell and taste were reported as incapacitating in 7,03% (19), followed by headache in 5,18% (14). Regarding ocular manifestations, ocular pain obtained a percentage of 4,44% (12) in scale 3, followed by sensitivity to light in 6,29% (17) in scale 2. Reported ocular symptoms mainly occurred between 1 to 3 days in 12,6% (34). 95,6% (258) of surveyed people were vaccinated against COVID-19. The following were the more frequently systemic symptoms reported as disabling after vaccination: headache in 8.5% (23), followed by muscle pain in 8,1% (22). Within the ocular manifestations, there was a prevalence of itching in 1.4% (4), followed by ocular dryness in 1,1% (3). These manifestations presented mainly between 1 to 3 days after vaccination in 40% (108) of the participants. Conclusions: Although vaccination against COVID-19 has been effective, positive cases persist in which the more frequently reported symptoms have been loss of smell and taste, headache, and runny nose; additionally, incapacitating eye pain has been reported. Regarding the symptoms presented after vaccination; muscle pain, headache and itchy eyes stand out.
dc.description.degreelevelPregradospa
dc.description.degreenameOptómetraspa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/12275
dc.language.isoes
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programOptometríaspa
dc.relation.references1. Sharma, A., Farouk, I. A., Lal, S. K., Martinez-Sobrido, L., & Toral, F. A. (2021). COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. https://doi.org/10.3390/v13020202
dc.relation.references2. Kai-Wang To, K., Sridhar, S., Hei-Yeung Chiu, K., Ling-Lung Hung, D., Li, X., Fan- Ngai Hung, I., Raymond Tam, A., Wai-Hin Chung, T., Fuk-Woo Chan, J., Jian-Xia Zhang, A., Chi-Chung Cheng, V., & Yuen, K.-Y. (2021). Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. https://doi.org/10.1080/22221751.2021.1898291
dc.relation.references3. Ochani, R., Asad, A., Yasmin, F., Shaikh, S., Khalid, H., Batra, S., Sohail, M. R., Mahmood, S. F., Ochani, R., Hussham Arshad, M., Kumar, A., & Surani, S. (2021). COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Le infezioni in medicina, 29(1), 20–36. https://pubmed.ncbi.nlm.nih.gov/33664170/
dc.relation.references4. Kai-Wang To, K., Sridhar, S., Hei-Yeung Chiu, K., Ling-Lung Hung, D., Li, X., Fan- Ngai Hung, I., Raymond Tam, A., Wai-Hin Chung, T., Fuk-Woo Chan, J., Jian-Xia Zhang, A., Chi-Chung Cheng, V., & Yuen, K.-Y. (2021). Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. https://doi.org/10.1080/22221751.2021.1898291
dc.relation.references5. Sen, M., Honavar, S. G., Sharma, N., & Sachdev, M. S. (2021). COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19. Indian Journal of Ophthalmology, 69(3). https://journals.lww.com/ijo/Fulltext/2021/03000/COVID_19_and_Eye__A_Review_ of_Ophthalmic.8.aspx
dc.relation.references6. Chen, L., Deng, C., Chen, X., Zhang, X., Chen, B., Yu, H., Qin, Y., Xiao, K., Zhang, H., & Sun, X. (n.d.). Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. https://doi.org/10.1111/aos.14472
dc.relation.references7. Meduri, A., Oliverio, G. W., Mancuso, G., Giuffrida, A., Guarneri, C., Rullo, E. V., Nunnari, G., & Aragona, P. (2020). Ocular surface manifestation of COVID-19 and tear film analysis. https://doi.org/10.1038/s41598-020-77194-9
dc.relation.references8. Aggarwal, K., Agarwal, A., Jaiswal, N., Dahiya, N., Ahuja, A., Mahajan, S., Tong, L., Duggal, M., Singh, M., Agrawal, R., & Guptaid, V. (2020). Ocular surface manifestations of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. https://doi.org/10.1371/journal.pone.0241661
dc.relation.references9. Ceran, B. B., & Ozates, S. (n.d.). Ocular manifestations of coronavirus disease 2019. https://doi.org/10.1007/s00417-020-04777-7/Published
dc.relation.references10. PAHO. (2021, May). Inmunization, Pan American Health Organization. https://www.paho.org/en
dc.relation.references11. Centro Nacional de Vacunación y Enfermedades Respiratorias (NCIRD), D. de E. V. (2022, February 4). Desarrollo de Vacunas contra el COVID-19. https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/distributing/steps-ensure- safety.html
dc.relation.references12. Strikas, R. A., Mawle, A. C., Pickering, L. K., & Orenstein, W. A. (2018). Active Immunization. In M. D. Long Sarah S., M. D. Prober Charles G., & M. D. M. P. H. Fischer Marc (Eds.), Principles and Practice of Pediatric Infectious Diseases (Fifth Edition, pp. 43-71.e4). https://doi.org/http://dx.doi.org/10.1016/B978-0-323-40181- 4.00006-2
dc.relation.references13. Ali, U. A., Sadiq, M. S., & Yunus, M. J. (2021). Cardiorenal syndrome in COVID-19. BMJ Case Reports, 14(4). https://doi.org/10.1136/bcr-2021-241914
dc.relation.references14. Zhong, Y., Wang, K., Zhu, Y., Lyu, D., Yu, Y., Li, S., & Yao, K. (2021). Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis. In Travel Medicine and Infectious Disease (Vol. 44). Elsevier Inc. https://doi.org/10.1016/j.tmaid.2021.102191
dc.relation.references15. Arias-Peso, B., & Rendón-Fernández, H. (2021). Conjuntivitis y COVID-19: la importancia de un reconocimiento precoz. Enfermedades Infecciosas y Microbiología Clínica, 39(2), 111. https://doi.org/10.1016/J.EIMC.2020.07.004
dc.relation.references16. Nasiri, N., Sharifi, H., Azam Bazrafshan, ;, Noori, A., Karamouzian, M., & Sharifi, A. (2021). Ocular Manifestations of COVID-19: A Systematic Review and Meta- analysis. J Ophthalmic Vis Res, 16(1), 103–112. https://doi.org/10.18502/jovr.v16i1.8256
dc.relation.references17. Chen, Y.-Y., Yen, Y.-F., Huang, L.-Y., & Chou, P. (2021). Manifestations and Virus Detection in the Ocular Surface of Adult COVID-19 Patients: A Meta-Analysis. https://doi.org/10.1155/2021/9997631
dc.relation.references18. Pérez-Bartolomé, F., & Sánchez-Quirós, J. (2021). Manifestaciones oftalmológicas del SARS-CoV-2: Revisión de la literatura. Archivos de La Sociedad Española de Oftalmología, 96(1), 32–40. https://doi.org/10.1016/J.OFTAL.2020.07.020
dc.relation.references19. Seirafianpour, F., Homa Pourriyahi, |, Milad, |, Mesgarha, G., Arash, |, Shaka, Z., & Goodarzi, A. (2022). A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. Dermatologic Therapy, 35. https://doi.org/10.1111/dth.15461
dc.relation.references20. Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M. H., Turner, D. L., Turner, R. J., Rajendran, C., & Jaganathan, K. S. (2021). Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. https://doi.org/10.3390/vaccines9050467
dc.relation.references21. Seirafianpour, F., Homa Pourriyahi, |, Milad, |, Mesgarha, G., Arash, |, Shaka, Z., & Goodarzi, A. (2022). A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. Dermatologic Therapy, 35. https://doi.org/10.1111/dth.15461
dc.relation.references22. Kadali, R. A. K., Janagama, R., Peruru, S., & Malayala, S. v. (2021). Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. International Journal of Infectious Diseases, 106, 376–381. https://doi.org/10.1016/J.IJID.2021.04.047
dc.relation.references23. National Center for Immunization and Respiratory Diseases. (2021, August 9). The Moderna COVID-19 Vaccine’s Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events.https://www. cdc.gov/vaccines/covid‑19/info‑by‑prod‑uct/moderna/reactogenicity.
dc.relation.references24. Seirafianpour, F., Homa Pourriyahi, |, Milad, |, Mesgarha, G., Arash, |, Shaka, Z., & Goodarzi, A. (2022). A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. Dermatologic Therapy, 35. https://doi.org/10.1111/dth.15461
dc.relation.references25. Ng, X. le, Betzler, B. K., Testi, I., Ho, S. L., Tien, M., Ngo, W. K., Zierhut, M., Chee, S. P., Gupta, V., Pavesio, C. E., de Smet, M. D., & Agrawal, R. (2021). Ocular Adverse Events After COVID-19 Vaccination. Ocular Immunology and Inflammation, 29(6), 1216–1224. https://doi.org/10.1080/09273948.2021.1976221
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_14cbspa
dc.rights.localAcceso cerradospa
dc.subjectManifestaciones oculares
dc.subjectInfección
dc.subjectVacunación
dc.subjectCOVID-19
dc.subject.ddcWW704
dc.subject.keywordsEye Manifestations
dc.subject.keywordsInfections
dc.subject.keywordsVaccination
dc.subject.keywordsCOVID-19
dc.titleComparación de las manifestaciones oculares durante el contagio por COVID-19 y después de la vacunación
dc.title.translatedOcular manifestations during COVID-19 infection and associated symptoms after vaccination.
dc.type.coarhttps://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Pregradospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Trabajo de grado.pdf
Tamaño:
482.19 KB
Formato:
Adobe Portable Document Format
Descargar

Colecciones

Optometría